Branch of medicine dealing with cancer
POPULARITY
Categories
1,161 episodes with Oncology
397 episodes with Oncology
368 episodes with Oncology
415 episodes with Oncology
334 episodes with Oncology
361 episodes with Oncology
157 episodes with Oncology
118 episodes with Oncology
112 episodes with Oncology
116 episodes with Oncology
116 episodes with Oncology
101 episodes with Oncology
77 episodes with Oncology
118 episodes with Oncology
205 episodes with Oncology
128 episodes with Oncology
77 episodes with Oncology
59 episodes with Oncology
50 episodes with Oncology
43 episodes with Oncology
69 episodes with Oncology
58 episodes with Oncology
53 episodes with Oncology
60 episodes with Oncology
84 episodes with Oncology
88 episodes with Oncology
41 episodes with Oncology
57 episodes with Oncology
41 episodes with Oncology
50 episodes with Oncology
78 episodes with Oncology
50 episodes with Oncology
54 episodes with Oncology
45 episodes with Oncology
37 episodes with Oncology
22 episodes with Oncology
57 episodes with Oncology
63 episodes with Oncology
44 episodes with Oncology
43 episodes with Oncology
28 episodes with Oncology
43 episodes with Oncology
23 episodes with Oncology
36 episodes with Oncology
38 episodes with Oncology
32 episodes with Oncology
76 episodes with Oncology
51 episodes with Oncology
27 episodes with Oncology
39 episodes with Oncology
29 episodes with Oncology
23 episodes with Oncology
17 episodes with Oncology
80 episodes with Oncology
At 25, Jace Yawnick was building a career in health and wellness sales, chasing growth, status, and the usual young adult fantasy of getting somewhere fast. Then his body stopped cooperating. Fatigue turned into chemotherapy. The diagnosis was primary mediastinal B cell non Hodgkin lymphoma, and the rest of his life split into before and after. Now in remission, he talks about cancer the way people actually live it, not the way nonprofits package it. He gets into survivorship, mental health, young adult isolation, and the deadening absurdity of prior authorization. One of the sharpest parts of the conversation lands on a simple American insult disguised as policy: treatment innovation means very little when insurance can still deny the scan, the drug, or the next step. Jace has seen that firsthand, including during routine monitoring after active treatment. This episode tracks what happens when a young cancer patient becomes a public voice and refuses to play mascot. It covers oncology, insurance, remission, advocacy, and the long mental hangover that follows survival. It also names the part too many institutions dodge: the system works great right up until it doesn't, and when it fails, patients get handed the bill, the panic, and a camera if they want anyone to care. RELATED LINKSJace Beats CancerJace Yawnick on LinkedImConquer Cancer ArticleCURE Today ArticlePyure BrandsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
A breast cancer diagnosis may feel like it changes your entire life in an instant, but it doesn't get to define who you are or make all your choices for you. On today's episode of Real Pink, we're joined by Amanda Sangemino, a remarkable young woman whose diagnosis came at an age when cancer was likely the last thing on her mind. What began with a concern that was initially dismissed ultimately led her to trust her instincts, advocate for herself, and make a series of personal decisions about her treatment and future. Throughout the process, she was determined not to let fear and cancer make every decision for her. Today, she'll talk about the choices that she made about fertility, surgical options and maintaining an active lifestyle and why trusting yourself can be one of the most powerful tools you have. Key Takeaways: Mindset can play a powerful role during treatment Trust your instincts and advocate for yourself Maintaining normalcy can be empowering Don't let cancer make every decision for you A strong support system makes a difference Chapters: 00:00 – Amanda's Breast Cancer Story Begins 01:28 – Finding a Lump and Receiving a Misdiagnosis 04:22 – Seeking a Second Opinion and Getting Answers 07:00 – Why Self-Advocacy Matters for Young Women 10:00 – Fertility, Menopause, and Treatment Decisions 14:43 – Choosing Surgery, Staying Active, and Building Support 23:09 – Amanda's Final Advice Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship.
In this episode, we review the high-yield topic of Endometrial Carcinoma from the Oncology section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
In this podcast, experts Hope S. Rugo, MD, FASCO; Fabrice André, MD, PhD; Nadia Harbeck, MD; and Heather McArthur, MD, MPH; discuss updates from the SERENA-6, evERA, PREcoopERA, and TRAK-ER trials of oral selective estrogen receptor degraders (SERDS) in patients with hormone receptor–positive/HER2-negative (HR+/HER2–) early, advanced, and metastatic breast cancer (MBC). These results were presented at European Society for Molecular Oncology (ESMO) Breast 2026.
Cancer is never convenient, and it never arrives when a patient is truly prepared, according to Daniel C. McFarland, DO, who began the most recent episode of Oncology On the Go with this sentiment. When individuals enter the high-stakes, highly coordinated world of oncology, they do so under extreme duress, often presenting the versions of themselves that are most under stress. In this environment, clinical teams frequently encounter behaviors that get unfairly lumped into the vague and pejorative category of the “difficult patient.” What happens when these challenges stem from an underlying personality disorder rather than just temporary situational anxiety? In this episode, McFarland was joined by psycho-oncology expert Kaleena Chilcote, MD, to unpack the inner workings of personality styles and disorders within oncologic science. Together, they explored the Diagnostic and Statistical Manual of Mental Health Disorders (DSM) diagnostic framework, spanning the eccentric, dramatic, and anxious categories. They discussed how these enduring, pervasive traits impact a patient's health care journey. Shifting the conversation away from the stigma of labels, McFarland and Chilcote delivered actionable, real-world advice for oncology teams. They discussed how to utilize objective, descriptive charting; initiate a pause to check your own provider emotions; and build highly consistent, structured boundaries. From managing frequent phone calls to intentionally scheduling short, high-frequency touchpoints, the pair provided a roadmap for turning interpersonal conflict into therapeutic collaboration, proving that underneath the defense mechanisms, every patient has a uniquely valuable strength to connect with. McFarland is the director of the Psycho-Oncology Program at Wilmot Cancer Center and a medical oncologist who specializes in head, neck, and lung cancer, in addition to being a psycho-oncology editorial advisory board member for the journal ONCOLOGY®. Chilcote is director of Psycho-Oncology in the Department of Palliative and Supportive Care at the Taussig Cancer Center, part of the Cleveland Clinic.
Season 3 of Prostate Talk continues with a deep dive into one of the most important topics in prostate cancer care: precision.In this second episode, Maude Pavageau welcomes Dr. Eduard Baco to discuss the critical role of accurate image fusion in prostate biopsy.From improving targeting accuracy to helping reduce missed diagnoses and supporting more personalized treatment decisions, this conversation highlights how technology is reshaping the prostate cancer journey.
In this episode, we review the high-yield topic of Hairy Cell Leukemia (HCL) from the Oncology section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
This week, we take a quick trip to Stockholm, Sweden, where ESTRO (European Society for Radiotherapy and Oncology) took place several weeks ago. A/Prof Steven David digs deep into the latest updates in the breast cancer radiation space, including hyperfractionation of treatment, the utilisation of AI for radiation planning (Archery Trial), and the DBCG RT Natural Trial, which examined whether omitting partial breast irradiation (PBI) after breast-conserving surgery was safe in those over 60 (spoiler: you should still give PBI).For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
In this episode, we review the high-yield topic of Choriocarcinoma from the Oncology section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
In this episode, we review the high-yield topic of Soft Tissue Tumors from the Oncology section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
At 20 years old, newly arrived from Puerto Rico and trying to build a future in science, Benjamin Suarez Jimenez found himself sitting in front of two senior faculty members accused of plagiarism. He knew the material. He had done the work. His mistake came from failing to cite class notes during an exam because nobody had told him that was expected. In a matter of minutes, he watched what felt like his entire career flash before him.On this episode of Standard Deviation, host Oliver Bogler examines the hidden architecture of academic science through the experiences of Dr. Benjamin Suarez Jimenez, Assistant Professor at the University of Rochester and a neuroscientist studying PTSD, anxiety, trauma, and spatial cognition through virtual reality and video game environments.Benjamin traces his path from Puerto Rico to the mainland United States, through the NIH, Columbia University, and eventually to leading his own laboratory. Along the way, he encountered a series of barriers that had little to do with scientific ability and everything to do with access to unwritten rules. From academic gatekeeping to grant writing expectations, he learned that success in biomedical research often depends on knowledge that never appears in a textbook.Oliver explores how those invisible obstacles shape careers, influence research funding, and determine who gains access to opportunity. The conversation also examines the Justice, Equity, Diversity, and Inclusion Program at the Life Science Editors Foundation, which pairs scientists from underrepresented backgrounds with experienced scientific editors. Through that mentorship, Benjamin transformed a critical grant proposal into a successful pilot award that helped launch an NIH R01 application.The discussion extends beyond one scientist's experience. Benjamin describes helping a former mentee navigate dissertation roadblocks that threatened her graduation, illustrating how institutional bureaucracy can delay careers and discourage talented researchers. Together, they explore the hidden administrative burden, cultural barriers, and bias that many scientists carry alongside their research, and what happens when someone who receives support turns around and opens the door for others.RELATED LINKSLife Science Editors FoundationBenjamin Suarez Jimenez LabDr. Benjamin Suarez JimenezBenjamin Suarez JimenezFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
In this episode, we review the high-yield topic of Platinum Analogs from the Oncology section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
Send us Fan MailIn this episode of the Life Science Success Podcast my guest is Simran Padam, MD, APMMC, Executive Director of Medical Affairs at Worldwide Clinical Trials. A physician with 17+ years guiding global studies, she shares insights on medical monitoring, complex oncology and hematology programs, and the clinical judgment behind drug development highlighted in her newsletter, The Medical Monitor's Desk.00:00 Show Intro and Guest01:49 Simran Career Journey04:22 Why CRO Variety Matters05:48 What Medical Monitors Do08:04 Protocol vs Reality09:43 Physicians Role Evolving11:14 Better Trial Decisions13:31 Newsletter Behind Scenes16:09 LinkedIn Newsletter Reach17:07 From Science to Execution19:18 Therapeutic Specialization21:20 Collaboration Across Teams23:05 Capabilities for Future25:16 Rapid Fire Inspiration32:44 Where to Connect34:09 Podcast Outro
Welcome to the Patient from Hell podcast! Live from ASCO 2026, we explore breakthroughs in clinical oncology, cancer research, AI healthcare tools, and targeted therapy for advanced cancer.Samira Daswani, Founder and CEO of Manta Cares and host of The Patient From Hell, sits down with Dr. Doug Blayney, Chief Medical Officer of Manta Cares and former ASCO President, for a candid debrief in between sessions at the 2026 ASCO Annual Meeting in Chicago.With 45,000 oncology professionals in attendance, ASCO is the largest gathering of cancer researchers and clinicians in the world. In this episode, Samira and Dr. Blayney break down what actually mattered: the clinical findings, the shifting treatment landscape, and what the research trends mean for patients navigating cancer today.This episode is for oncologists, cancer researchers, and anyone who wants to understand where the field is heading.Topics covered, with more to come in our next episode:Key clinical findings from ASCO 2026Trends shaping experimental and clinical oncologyWhat high attendance and collaboration signals for the future of cancer researchWhat patients should know coming out of this year's conferenceCHAPTERS:0:00 - ASCO 2026 Annual Meeting Live from Chicago0:27 - Artificial Intelligence (AI) in Oncology & Patient Experience1:19 - Healthcare AI Challenges: Misinformation & Clinician Deskilling2:03 - Pancreatic Cancer Breakthrough: New RAS/KRAS Targeted Therapy2:30 - Lung Cancer Advancements: ALK Mutations & PD-L1 Data3:01 - Breast Cancer Innovation: Oral SERDs & ESR1 Biomarkers3:41 - Next Episode Preview & Wrap UpSubscribe for frequent breakdowns of cancer research, treatment news, patient stories, and guidance and support for people in treatment for cancer. Drop a comment with the topics or trials you want us to cover next!
This week Sara Erger comes on the show talking women's health. She touches on what types of screenings women should be getting, and when the best time is to start. Erger also highlights different types of cancers and HPV risks found in women, and what can be done to prevent this. In addition to this, Erger shines a light on the the rise of colon/rectal cancers in younger age ranges and cancer risks, giving invaluable information to help aid those searching for some answers. Listen To The Local Matters Podcast Today! News Talk 94.1
In this week's episode, Blood editor Dr. Philippe Armand interviews Drs. Manali Kamdar and Nancy L. Bartlett on their latest review article published in Blood titled “From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma”. They discuss the how the advent of chimeric antigen receptor T cells, antibody-drug conjugates, and bispecific antibodies all show major increases in efficacy over legacy chemotherapy-based regimens. They also share their insights on how to transform treatment paradigms in light of these breakthroughs.
Send us Fan MailA cancer diagnosis can change everything in an instant. One conversation. Three words: "You have cancer." Suddenly, patients and families are faced with uncertainty, fear, and countless questions about what comes next.In this episode of MedStar Health DocTalk, host Debra Schindler sits down with medical oncologist and hematologist Dr. Ankit Madan of MedStar Southern Maryland Hospital Center, to discuss the critical first steps after a cancer diagnosis. Dr. Madan explains how patients move from diagnosis to treatment, how cancer is staged, and why building a multidisciplinary care team is essential for the best possible outcomes.The conversation explores the emotional impact of hearing a cancer diagnosis, the importance of patient navigators, social workers, nutritionists, mental health professionals, and the role patients play as active partners in their own care. Dr. Madan also discusses treatment advances, clinical trials, immunotherapy breakthroughs, second opinions, and practical advice for patients and families navigating one of life's most challenging journeys.Whether you or a loved one has recently been diagnosed with cancer, this episode offers guidance, reassurance, and expert insight into what happens after the diagnosis—and how patients can move forward with confidence and support.Topics covered:• Coping with the emotional impact of a cancer diagnosis• Understanding cancer staging and treatment planning• The role of biopsies, CT scans, PET scans, and additional testing• Building a multidisciplinary cancer care team• Patient navigators, social workers, and support services• Shared decision-making and patient autonomy• When to seek a second opinion• Clinical trials and emerging cancer treatments• Immunotherapy and advances in cancer care• Nutrition, exercise, and mental health during treatment• Cancer survivorship and ongoing surveillanceTo learn more about cancer care at MedStar Health, visit MedStarHealth.org/Cancer.For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.
Oncology drug development is becoming more complex, and bioanalysis can no longer be treated as simple drug measurement.Sponsored by Leucentra, https://leucentra.com/Inspired by science, empowered by IT. Leucentra helps life science and healthcare organizations evaluate, implement, and get more value from technology that supports innovation.In this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe speak with Dr. Lakshmi Amaravadi, Head of Oncology Bioanalysis at AstraZeneca, live from AAPS PharmSci 360 in San Antonio.Dr. Amaravadi unpacks why biomarker validation is not one-size-fits-all, how context of use should guide scientific decision making, and why fit-for-purpose validation matters in modern oncology drug development.The conversation explores:00:00 Why oncology bioanalysis is becoming more complex02:12 FDA biomarker validation guidance and industry response04:27 What “fit for purpose” means in practice06:38 PK assay validation vs biomarker assay validation07:52 What drives Dr. Amaravadi's work in translational science10:48 Why validation is not a checkbox exercise12:19 Advice for young scientists entering bioanalysis15:12 Why oncology drug development is uniquely complex18:17 ADCs, bispecifics, T-cell engagers, and conditional T-cell engagers19:38 Why bioanalysis now requires understanding biology20:46 Dr. Amaravadi's path from molecular biology to bioanalysis24:34 Critical reagent management in complex oncology assays26:42 Validation, qualification, and context of use29:03 Final thoughts from AAPS PharmSci 360This episode is especially relevant for scientists, bioanalytical leaders, translational researchers, clinical pharmacologists, oncology development teams, biomarker scientists, and anyone working at the intersection of drug development, assay validation, and precision medicine.Dr. Amaravadi discusses how oncology programs now involve ADCs, bispecifics, T-cell engagers, conditional T-cell engagers, complex linkers, multiple measurable species, immunogenicity considerations, and biomarker strategies that require deeper biological understanding. As she explains in the episode, the future of oncology bioanalysis is not simply measuring what is present. It is understanding what the measurement means in the context of the biology and the development decision.Follow BioTalk Unzipped for conversations with leaders in biotech, pharma, bioanalysis, clinical development, translational science, regulatory strategy, and the future of medicine.GuestDr. Lakshmi Amaravadihttps://www.linkedin.com/in/lakshmi-amaravadi/HostsGregory Austinhttps://www.linkedin.com/in/gregoryaustin1/Dr. Chad Briscoehttps://www.linkedin.com/in/chadbriscoe/Sponsor: LeucentraRelated LinksCelerionhttps://www.celerion.com/
In this sponsored episode of The Top Line, experts from Myriad Genetics join host Stephanie Butler to examine how tumor-informed molecular residual disease, or MRD, testing is beginning to redefine what early insight can mean in oncology drug development. As biomarker-driven therapies become more precise, the ability to understand response earlier and more clearly is increasingly being viewed as foundational to smarter development strategy. The discussion looks at how ultrasensitive, tumor-informed MRD assays can help track response over time, potentially surface deeper signals earlier and inform decisions that shape trial design, patient selection and regulatory direction. It also considers why these capabilities may become more important as oncology programs face growing pressure to balance speed, flexibility and evidence generation. Listeners will hear why early diagnostic strategy is increasingly seen as a competitive differentiator, how MRD can help teams make better decisions sooner and why its role in oncology development is expected to continue to evolve and expand.See omnystudio.com/listener for privacy information.
Dr. Sarah Matt trained as a burn surgeon, working in a field where patients arrive with catastrophic injuries and survival depends on speed, skill, and resources. She left the bedside after confronting a limit that medicine does not like to admit. One physician can only see so many people in a day. The system surrounding those patients decides the rest. She moved into health technology, held leadership roles in startups, and built global infrastructure at Oracle to scale care across populations. Then she watched billions of dollars in digital health and AI initiatives stall out when they hit real clinical environments.This episode follows that pivot from surgeon to strategist and back into direct patient care in rural New York, where she now treats uninsured patients, migrant workers, and communities pushed to the margins. The conversation centers on a persistent failure across healthcare systems. Products get built for regulators, executives, and investors instead of the people who use them. The result shows up in failed adoption, broken workflows, prior authorization delays, and rising physician burnout.The discussion cuts through health policy language and lands on lived consequence. The system rewards speed over usability, scale over trust, and compliance over care. Patients absorb the fallout. Physicians carry the liability. The incentives remain intact.RELATED LINKSDr. Sarah MattThe Borderless Healthcare RevolutionThe Clinical RealistJessica FedererSovatoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Better Edge : A Northwestern Medicine podcast for physicians
In this episode of Better Edge, Transplant Hepatologist Laura Lulik, MD moderates a panel discussion about the Northwestern Medicine Liver Transplant Tumor Clinic. The conversation covers advances in imaging, systemic therapies and innovative procedures, as well as the clinic's multidisciplinary approach.The panel includes: • Daniel Borja, MD, transplant surgeon• Aparna Kalyan, MD, medical oncologist • Robert Lewandowski, MD, interventional radiologist• Amira Borhani, MD, abdominal radiologist
Listen to JCO's Art of Oncology article, "A Shopping List" by Dr. Michael Krasovitsky, who is a medical oncologist at St. Vincent's Hospital in Sydney, Australia and senior lecturer at the University of New South Wales. The article is followed by an interview with Krasovitsky and host Dr. Mikkael Sekeres. Dr. Krasovitsky shares a story of nourishment, serendipity and the unexpected bonds that connect oncologists with patients. LINK TO FULL TRANSCRIPT
In a live X Spaces discussion hosted by CancerNetwork® in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT), Marc J. Braunstein, MD, PhD, and Sofia Zahid, MD, highlighted noteworthy presentations and abstracts in hematologic oncology at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Together, they discussed the data that may shake up clinical practice across different multiple myeloma, leukemia, and lymphoma populations.
“I think it’s the most exciting period in cancer discovery and development that I’ve experienced over the last 25 years,” says Susan Galbraith, executive vice president of oncology R&D at AstraZeneca. Galbraith joins Bloomberg Intelligence analyst Sam Fazeli fresh from the ASCO conference to unpack how ctDNA, earlier intervention and next-generation oncology platforms could reshape cancer care. They discuss AstraZeneca’s Stride regimen in liver cancer, Serena-6 in breast cancer, progress in pancreatic cancer and the company’s push across ADCs, bispecifics, CAR-T and radio conjugates.See omnystudio.com/listener for privacy information.
Send us Fan MailS4E4 The Oncology Journal Club Podcast In this special ASCO 2026 edition of The Oncology Journal Club, Craig Underhill, Chris Jackson and Kate Clarke unpack some of the meeting's most talked-about studies and discuss what they could mean for clinical practice.From the PROTEUS trial in high-risk prostate cancer and promising advances in RET fusion-positive lung cancer, to a rare sarcoma study demonstrating the potential of CDK4 inhibition, the team explores the data behind the headlines and highlights the challenges of translating trial results into real-world care.The episode also dives into what many are calling the breakthrough study of the meeting – the RESOLUTE-302 trial of daraxonrasib in previously treated pancreatic cancer. With a striking overall survival benefit in a disease that has seen few meaningful advances, the results sparked excitement throughout the oncology community.Along the way, the panel reflects on the atmosphere at ASCO, emerging trends in precision oncology, and how new therapeutic approaches such as KRAS inhibitors, bispecific antibodies and antibody-drug conjugates are reshaping the future of cancer treatment.The Oncology Journal Club Podcast is hosted by Professor Craig Underhill, Dr Kate Clarke and Professor Chris Jackson, and proudly produced by The Oncology NetworkVisit oncologynetwork.com.au for Show Notes, to send us Voice Notes and more information. And to download your bingo card if you'd like to play along with the team!
Dr. Pedro Barata and Dr. Bridget Keenan discuss the innovative bioengineering allowing clinicians to target historically "immune-cold" tumors, the logistical evolution of bringing bispecific therapies safely into outpatient community clinics, and the complex future of predictive biomarkers and resistance mechanisms. LINK TO FULL TRANSCRIPT
In a live X Spaces discussion hosted by CancerNetwork® in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT), Marc J. Braunstein, MD, PhD, and Sofia Zahid, MD, highlighted noteworthy presentations and abstracts in hematologic oncology at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Together, they discussed the data that may shake up clinical practice across different multiple myeloma, leukemia, and lymphoma populations.Braunstein is an associate professor in the Department of Medicine and course co-director of the Hematology/Oncology System at NYU Grossman Long Island School of Medicine, as well as the fellowship program director of Hematology/Oncology at NYU Langone Health. Zahid is a first-year fellow at NYU Grossman Long Island School of Medicine.The discussion focused on the following abstracts:· Abstract 7512o Combining belantamab mafodotin-blmf (Blenrep) with daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone produced rapid activity among patients with transplant-ineligible newly diagnosed multiple myeloma in the phase 1/2 BelaDRd study (EUCT-2024-515634-32).o The progression-free survival (PFS) benefits observed in the trial support further evaluation of the quadruplet in a phase 3 study compared with other novel combination regimens in NDMM.· Abstract 6505o Revumenib (Revuforj) maintenance therapy after allogeneic stem cell transplantation showed feasibility in a heavily pretreated cohort of patients with acute myeloid leukemia (AML).o Outcomes appeared favorable vs historical cohorts, supporting prospective assessment of maintenance menin inhibition among those with AML.· Abstract 1503o In a retrospective analysis of electronic medical records for 293 patients who received CAR T-cell therapy for lymphoma (n = 175), multiple myeloma (n = 106), or B-cell acute lymphoblastic leukemia (n = 12), outpatient monitoring was associated with significantly fewer hospital days without increased emergency department visits or 30-day mortality.o These findings show the potential for lower healthcare utilization for patients who receive CAR T-cell therapy in the outpatient setting.· Abstract LBA7000o Adding tafasitamab (Monjuvi) and lenalidomide to rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) significantly improved PFS vs R-CHOP alone among those with newly diagnosed diffuse large B-cell lymphoma (DLBCL) in the phase 3 frontMIND trial (NCT04824092).o The data may support tafasitamab plus lenalidomide and R-CHOP as a potential new standard of care in the frontline treatment of patients with cell-of-origin subtypes of high-risk DLBCL.References Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, et al. Belantamab mafodotin with daratumumab, lenalidomide, and dexamethasone in transplant-ineligible, newly diagnosed multiple myeloma patients: phase 1/2 BelaDRd study. J Clin Oncol. 2026;44(suppl 16):7512. doi:10.1200/JCO.2026.44.16_suppl.7512 Goulart H, Okeleji O, DiNardo CD, et al. Revumenib as maintenance for AML following allogeneic stem cell transplantation. J Clin Oncol. 2026;44(suppl 16):6505. doi:10.1200/JCO.2026.44.16_suppl.6505 Bowen SG, Abdallah N, Pritchett JC, et al. Impact of outpatient CAR T-cell therapy administration on healthcare utilization in patients with hematologic malignancies. J Clin Oncol. 2026;44(suppl 16):1503. doi:10.1200/JCO.2026.44.16_suppl.1503 Lenz, G, Trněný M, Burke JM, et al. frontMIND: phase 3 study of tafasitamab (Tafa) plus lenalidomide (Len) and R-CHOP for patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2026;44(suppl 17):LBA7000. doi:10.1200/JCO.2026.44.17_suppl.LBA7000
Today on National Cancer Survivor's Day, we're joined by a remarkable performer whose strength, vulnerability, and resilience have inspired millions around the world. She has taken the stage as a backup vocalist for numerous top artists and most recently dazzled the crowds on the biggest tour in music history with global superstar Taylor Swift. However, audiences were moved even more deeply when she chose to publicly share something far more personal – her breast cancer journey. After Jeslyn Gorman's diagnosis become known through The Eras Tour docuseries, fans witnessed the emotional reality of navigating cancer while stepping away from a career and community she loves so deeply. From continuing to tour in the early days of diagnosis, to facing treatment side effects and returning to the stage immediately following treatment, her story is one of courage, grace and resilience. Today, Jeslyn opens up about the support she received, what survivorship looks like now and most importantly, shares an empowering message for young women about listening to their bodies, advocating for their health, and never underestimating the importance of early detection. Key Takeaways: Early detection can save lives. You can experience joy and fear at the same time. A strong support system makes a major difference. Recovery is gradual and requires patience. Cancer changes your life, but it doesn't define it. Chapters 00:00 – Jeslyn's Breast Cancer Diagnosis 05:24 – Continuing to Perform After Diagnosis 07:38 – Going Public With Her Cancer Story 13:22 – Breast Health and Self-Advocacy 18:07 – Support From Family, Friends, and the Tour Community 22:17 – Staying Positive During Treatment 25:17 – Chemotherapy and Physical Recovery 31:49 – Hair Loss and Identity Learn more at realpink.komen.org and komen.org Real Pink, by Susan G. Komen, shares real stories and expert insights to support people navigating breast cancer, from diagnosis through survivorship. 37:29 – Life After Treatment and Survivorship
This episode tells the story of how one man, Jake Messier, who is living with metastatic male breast cancer, is challenging the stigma surrounding this disease, which affects 1% of all breast cancer patients. It's an important reminder that not all cancers are funded and researched equally, and that behind every statistic is a person trying to live a normal life.Jake has used his lifelong PR skills to turn what is a diagnosis unlike any other into a conversation about equity, resilience and a deep societal stigma. This conversation should also serve as a reminder of how patients perceive the healthcare system and that communication is key when treating patients, many of whom are vulnerable.A huge thank you to Jake for coming on the show. If you want more information, see Jake's website: https://www.theguywithstage4breastcancer.com/For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
Are medical advancements closing or widening medical disparities? Eugene Manley, Jr., Ph.D., founder and CEO of the STEMM & Cancer Health Equity Foundation, breaks down why equity is still not completely measurable in clinical trials, what proper representation in studies is, and how certain demographics are at a disadvantage for biomarker tests compared to other groups with host Deborah Borfitz. Their conversation explores whether health equity in cancer trials is different compared to commonly occurring diseases and if basket and umbrella trials may help the move the needle. Plus, the latest news on a pioneering phage therapy service, a unique cardiac arrest pilot study, new primary endpoints for cancer trials, and trial disruptions threatening diversity. Listen and let us know in a review: where do you think our time and resources are most needed for equity? Show Notes News Roundup Compassionate use phage therapy Article in Nature Medicine Press release from Monash University Sudden cardiac death research Study in Prehospital Emergency Care News on the University of Cincinnati website New endpoints for cancer trials Consensus paper in The Lancet Oncology News on the Medical University of Vienna website USC and Tempus strategic collaboration News on the Keck School of Medicine of USC website Trial disruptions threaten diversity Article in the Journal of Medical Internet Research Misinterpreting effects of Alzheimer's drugs Research letter in JAMA Neurology News from Brown University School of Public Health Guest Eugene Manley, Jr., Ph.D., founder and CEO of the STEMM & Cancer Health Equity Foundation The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.
In this Review series episode, Blood associate editor Dr. Diane Krause interviews contributing authors from the Review Series on Clonal tracking in Hematopoiesis published in volume 147 issue 23 of Blood. Dr. Alejo E. Rodriguez-Fraticelli speaks to the development of his paper, "Clonal tracing of blood stem cells across mouse and human lifespans”, which provides a detailed overview of the experimental approaches that make clonal analysis possible, and which approaches are most appropriate to use to address specific questions. Dr. Shalin H. Naik speaks about how different clonal tracking approaches have been used to address the central question of clonal fate specification of stem and progenitor cells to specific lineages in “The evolution of hematopoietic models through a clonal lens”. Finally, Dr. Federico Gaiti speaks about “Methylation-based lineage tracing in cancer”, which takes these ideas into the context of cancer, focusing on how DNA methylation can be used to reconstruct clonal relationships.
SMH's Kolschowsky Research and Education Institute is enrolling patients in a research study evaluating LINFU (Low-Intensity Non-Focused Ultrasound), an emerging screening technology designed to help doctors identify precancerous changes in people at high risk for pancreatic cancer, but who have no signs or symptoms of the disease. Kenneth Meredith, MD, chief of gastrointestinal oncology at SMH's Brian D. Jellison Cancer Institute and principal investigator of the local study, says the screening represents an important step forward in pancreatic cancer research. You can also watch the video recording on our Vimeo channel here. For more health tips & news you can use from experts you trust, sign up for Sarasota Memorial's monthly digital newsletter, Healthe-Matters.
In this episode, we review the high-yield topic of Teratoma from the Oncology section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
The Cancer Pod: A Resource for Cancer Patients, Survivors, Caregivers & Everyone In Between.
Leave a message and let us know what you liked about the episode!Survivor's guilt is a common and not often talked about emotional experience after cancer. Dr. Leah Sherman sits down with returning guest Natasha Ewa, licensed clinical social worker and founder of I Thrive Therapy and Wellness, for an honest conversation about what survivor's guilt actually looks like, why body image after cancer is so personal, and what healing can feel like on the other side.The conversation widens to cover grief over pre-cancer identity, hypervigilance, reconstruction decisions, and Natasha's documentation of her own DIEP flap experience and complications.Whether you're navigating survivorship yourself or supporting someone who is, this one meets you where you are.Visit the I Thrive Therapy and Wellness websiteFollow Natasha on InstagramSupport the showBecome a member of The Cancer Pod Community! Gain access to live Q&As, exclusive content, and so much more! Join us today on Buy Me a Coffee or on Patreon!Check out our website! Looking for more information? We have blogs, merch, and all of our episodes listed by season and category. Shop our favorite reads! We've joined with Bookshop.org to offer some of our fave books!Buy our merch! Whether it's a cozy hoody or a handy water bottle, we have something for everybody.Have a comment or suggestion? Email us at info (at) thecancerpod (dot) com Follow us wherever you browse. We're always @TheCancerPod:InstagramBlueskyFacebookLinkedInYouTubeTHANK YOU!!
Payer & Provider Dynamics: Addressing Non-Medical Switching in Oncology for CLL/SLL On this episode guest host Ryan Haumschild, PharmD, MS, MBA, CPEL, Vice President of Pharmacy at Emory University and Emory Health Plan, Winship Cancer Institute, discusses the real-world impact of non-medical switching in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) with Timothy Mok, Manager of Clinical Utilization Intelligence at Kaiser Permanente and board-certified oncology pharmacist, focusing on the drivers behind switching, the risks of disrupting effective therapy, and how shared decision-making and dose modification can help maintain adherence and improve patient outcomes. Sponsored by Abbvie. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/
Jamie Metzl is a writer, futurist, and leading thinker on artificial intelligence, biotechnology, genetics, geopolitics, and the future of humanity. He is the author of Hacking Darwin, Superconvergence, and The AI Ten Commandments, and has worked across international affairs, human rights, global policy, and emerging technologies. In this episode, I speak with Jamie Metzl about artificial intelligence and the present and future of humanity. We begin with Jamie's smile and his particular kind of optimism, one that does not avoid darkness but insists on looking directly at it. From there we move into grief: the loss of his father, the pain of war, the emotional cost of technological acceleration, and the things we may already be losing without knowing how to mourn them. Jamie speaks about the need to stay connected to life even inside the cave of grief, the importance of zero-technology spaces, the danger of algorithms that monetize our attention, and why human creativity, presence, embodiment, and love remain irreplaceable. This is not a conversation about whether AI is good or bad. It is a conversation about what kind of humans we will need to become in order to meet the future without surrendering our humanity.As always, your comments are very valuable to me. Thank you for sharing and co-creating better questions with me. With love,Victor_______________________________________________________Don't want to miss the premiere of new episodes?Get them straight to your inbox. Sign up here: unique-author-3554.kit.com/volver-al-futuroMore content at:
In the late 1980s, a child exposed to fallout from the Chernobyl disaster lay in a hospital bed while doctors told his family there were no clear answers and no reliable path forward. Decades later, that same child, Yan Leyfman, walks into exam rooms as a hematology oncology fellow, expected to deliver clarity inside a system that still runs on delay, uncertainty, and institutional self preservation.This episode traces the throughline from early life shaped by radiation exposure and hospice level uncertainty to a career inside academic medicine, translational research, and oncology media. Yan built his identity around survival and usefulness, moving from patient to physician while carrying the memory of what it feels like to sit on the other side of the table. He helped launch MedNews Week during the COVID crisis to push back on misinformation and expand access to medical knowledge, stepping into a public role while still in training.The conversation stays grounded in the friction between personal narrative and system reality. Clinical training demands efficiency, hierarchy, and emotional distance. Cancer care demands time, clarity, and human connection. Those forces collide in real patient encounters where prior authorization delays, insurance barriers, and fragmented care pathways shape outcomes as much as any treatment protocol.Yan speaks openly about mentorship, belonging, and the drive to make meaning out of survival. The discussion pushes further into what the healthcare system actually rewards, what it quietly strips away, and how quickly empathy can erode under institutional pressure. The episode also examines the role of medical media, where education, industry influence, and narrative control often blur together.This is a conversation about identity under construction, about what happens when someone who remembers powerlessness steps into a role that carries authority, and about whether that memory can survive long enough to change anything.RELATED LINKSYan Leyfman on LinkedInYan Leyfman on InstagramSurviving ChernobylFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
In this episode, we review the high-yield topic of Pilocytic Astrocytoma from the Oncology section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
In this episode of Data in Biotech, host Ross Katz sits down with Arvind Rao, Professor of Computational Medicine and Bioinformatics at the University of Michigan, for a discussion on the gap between what biomedical AI can do and what it can reliably be trusted to do in clinical practice. Arvind's research sits at the intersection of computational oncology and AI governance and his lab works across H&E histopathology, multiplex immunofluorescence, spatial transcriptomics, and single-cell RNA sequencing, not just to build predictive models, but to understand the full lifecycle from data to model to inference, and to ask where that lifecycle can be trusted and where it can't. The conversation moves through two of his recent papers on SPIFEE, a graph-based framework that replaces scalar interaction scores in the tumor microenvironment with spatially resolved functional representations, and a multimodal framework that traces a path from stained tissue slides to nominated drug targets via morphological pattern discovery and spatial transcriptomic mapping. What you'll learn in this episode: >> Why the field's central failure is not algorithmic but translational and the gap between a model that performs well on a benchmark and one that can be consistently trusted in a high-stakes clinical setting >> How SPIFEE replaces the conventional scalar edge representation of cell-cell interactions in the tumor microenvironment with spatially resolved functional edges >> How Arvind's multimodal framework moves from H&E pathology slides labeled with clinical outcomes, through morphological pattern discovery via multiple instance learning, to spatial transcriptomic mapping, to the nomination of molecular mechanisms and actionable drug targets >> Why Goodhart's Law applies directly to foundation model evaluation in biology >> What the AI literacy gap costs when it goes unaddressed in healthcare and pharma organizations Meet our guest: Arvind Rao is a Professor of Computational Medicine and Bioinformatics, with a joint appointment in Radiation Oncology, at the University of Michigan. His research focuses on establishing trust in biomedical AI predictions across the full data-to-decision pipeline, integrating H&E histopathology, spatial transcriptomics, multiplex immunofluorescence, and single-cell RNA sequencing to build models that are predictive, interpretable, and biologically credible. Alongside his research, Arvind develops AI literacy programs for healthcare and pharma professionals, helping clinical and procurement teams evaluate and govern AI systems with the rigor those decisions demand. Connect with Arvind Rao on LinkedIn: https://www.linkedin.com/in/arvind-rao-3301301ba/ About the host: Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Ross Katz on LinkedIn: https://www.linkedin.com/in/b-ross-katz/ Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode! Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn. https://www.linkedin.com/company/corrdyn/
In this episode Dr. Patrick Moore, MD (oncologist and hematologist, Riverside Cancer Institute) explains the difference between oncology and hematology, what common conditions we treat, and why early detection matters. Learn how cancer screening, blood tests (CBC), and routine primary care visits can catch problems early so treatment — from surgery to chemotherapy and targeted therapy — can be most effective. Friendly, clear guidance for patients and families navigating cancer care.
Malignant Bowel Obstruction, VTE and Goals of CareMaster malignant bowel obstruction, cancer-associated thrombosis, and goals-of-care conversations in hospitalized patients with advanced cancer. Learn practical approaches to symptom management, anticoagulation decisions, and navigating high-stakes discussions around prognosis and hospice care. We're joined by Dr. Jensa Morris, @JensaMorrisMD (Yale School of Medicine).Claim free CME for this episode at curbsiders.vcuhealth.org!Show Segments Intro Picks of the Week Case 1: Malignant small bowel obstruction: definitions, initial management, medications, NG tubes, nutrition, and procedural options Case 2: Cancer-associated VTE: choice of anticoagulant, treatment duration, unusual thromboses, and anticoagulation with brain metastases Case 3: Goals of care: prognosis, performance status, palliative care, hospice and end-of-life planningTake Home Points Outro Credits Writer, producer, and show notes: Reaford Blackburn, Jr., MD Infographic, Cover Art: Caroline Coleman, MD Hosts: Monee Amin, MD and Meredith Trubitt, MD Reviewer: Rahul Ganatra, MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Jensa Morris, MD Sponsor: Continuing Education CompanyVisit CMEmeeting.org/curbsiders and use promo code Curb30 for 30% off all online courses and webcasts. Sponsor: LocumstoryLocumstory.com is literally just a free, unbiased resource dedicated to educating physicians about locums.Sponsor: Mint MobileTo get your new wireless plan for just 15 bucks a month, go to mintmobile.com/CURB.
In this episode, we review the high-yield topic of Retinoblastoma from the Oncology section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
This episode originally aired in November 2023. When someone has metastatic breast cancer, it is scary for them - and for you! What can you do to really help? What should you say? Is it better to just listen? Today's guest received a de novo metastatic diagnosis in January 2021 and then elected to retire early from a 30-year technology sales career in order to slow life down and to focus on family, friends and thriving with MBC. Carlee Dixon's surprise diagnosis also inspired her to learn as much as possible about breast cancer and take every opportunity to educate friends and acquaintances about breast cancer prevention and the day to day reality. Today, Carlee is here to shed some light on how to best support those who are living with metastatic breast cancer.
In this episode of Precision and Progress: Radiotherapy in Oncology, hosts Hirsch Matani, MD, and Elizabeth Zhang-Velten, MD, PhD, welcomed Binh T. Ngo, MD, to discuss the evolving role of radiation, systemic therapy, and multidisciplinary care for patients with melanoma and other skin cancers.Dr Matani is a clinical assistant professor of radiation oncology at the Keck School of Medicine of the University of Southern California (USC) and a radiation oncologist at the USC Norris Comprehensive Cancer Center. Dr Zhang-Velten is a radiation oncologist and a clinical assistant professor with Keck Medicine of USC. Dr Ngo is an assistant professor of dermatology at Keck Medicine of USC.In their discussion, Drs Matani, Zhang-Velten, and Ngo broke down how surgical approaches, radiation, and systemic therapy all play roles in the treatment of patients with skin cancer. Dr Ngo highlighted key prevention strategies that patients should be advised on, along with recommended follow-ups for patients who are at higher risk or those who underwent prior solid organ or hematologic transplants.The trio also discussed how the use of radiation for patients with skin cancer varies from techniques used for patients with tumors located within deeper organs, and they also highlighted how radiotherapy approaches could be applied for patients with tumors that would be difficult to surgically resect.
Jason Kirchick MPH, MSN, RN, CNL, MEDSURG-BC is an inpatient Hematology and Oncology nurse at the University of Vermont Medical Center where he cares for patients with blood cancers and solid tumors at every stage of illness. Before nursing, Jason worked as a firefighter and EMT, a background that gave him an intimate understanding of […] The post Code Status: Clearly Communicating the Nuances of Emergency Care Options (HLOL #272) appeared first on Health Literacy Out Loud Podcast.
In this episode, we review the high-yield topic of Ductal Carcinoma In Situ (DCIS) from the Oncology section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
What happens when a successful oncologist leaves clinical practice to help develop cancer treatments on a global scale? In this episode of The Lebanese Physicians Podcast, Dr. Safi Shahda shares his journey from academic oncology to leadership roles at Eli Lilly, Intellia Therapeutics, and AstraZeneca. We discuss career transitions, pharma misconceptions, innovation, AI in drug development, mentorship, and how physicians can expand their impact beyond the bedside. #LebanesePhysiciansPodcast #PharmaCareers #Oncology #ClinicalResearch #DrugDevelopment #MedicalLeadership #PhysicianCareer #AstraZeneca #Biotech #HealthcareInnovation #ArtificialIntelligence #CancerResearch #MedicalEducation #CareerGrowth #PhysicianLife #Medicine #Subscribe #Podcast #Healthcare #clinicaltrials @thelebanesephysicianspodcast @astrazeneca On all podcast apps Website: https://thelebanesephysicianspodcast.podbean.com
In this episode, we review the high-yield topic of Cholangiocarcinoma from the Oncology section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
Matthew Zachary is a brain cancer survivor, healthcare advocate, founder of Stupid Cancer and We the Patients, and host of Out of Patients. In April 2026, he returned to the stage at Merkin Hall near Lincoln Center for his first solo public piano concert in almost 22 years while launching his debut book, We the Patients: Understanding, Navigating, and Surviving America's Healthcare Nightmare.What unfolded became far larger than a concert.Over 2 hours, survivors, clinicians, advocates, nonprofit founders, journalists, pharmaceutical sponsors, and healthcare insiders gathered in one room to reflect on 30 years of survivorship, institutional failure, accidental advocacy, and the emotional afterlife of cancer. The evening moved through original piano performances, live chapter readings, and deeply personal conversations about infertility, disability, financial toxicity, insurance denials, grief, burnout, and what happens when patients spend decades navigating systems designed around transactions instead of continuity.Guests including Wendell Potter, Maimah Karmo, Craig Lustig, Shelly Fuld Nasso, Tamika Felder, and others reflected on how the modern cancer advocacy movement emerged largely because patients built parallel systems where healthcare infrastructure failed to meet human needs. The conversation explored how prior authorization, reimbursement incentives, administrative fragmentation, and institutional distrust continue shaping the patient experience across oncology and survivorship.The performance also marked a deeply personal milestone. After brain cancer compromised his left hand at age 21, Zachary spent 6 months rehabilitating both hands to return to public performance for the first time in over 2 decades. The result became part concert, part civic gathering, and part historical record of a generation of survivors who refused to disappear quietly.RELATED LINKSMZLIVE Official WebsiteMZLIVE YouTube VideoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
In this episode, we review the high-yield topic of Insulinoma from the Oncology section at Medbullets.comFollow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets
© 2020-2026 Ivy Podcast Discovery LLC
